ELX-02 Generates Protein via Premature Stop Codon Read-Through without Inducing Native Stop Codon Read-Through Proteins.
Journal
The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
07
02
2020
accepted:
30
04
2020
pubmed:
8
5
2020
medline:
13
11
2020
entrez:
8
5
2020
Statut:
ppublish
Résumé
ELX-02 is a clinical stage, small-molecule eukaryotic ribosomal selective glycoside acting to induce read-through of premature stop codons (PSCs) that results in translation of full-length protein. However, improved read-through at PSCs has raised the question of whether native stop codon (NSC) fidelity would be impacted. Here, we compare read-through by ELX-02 in PSC and NSC contexts. DMS-114 cells containing a PSC in the
Identifiants
pubmed: 32376628
pii: jpet.120.265595
doi: 10.1124/jpet.120.265595
doi:
Substances chimiques
Codon, Terminator
0
ELX-02
0
Furans
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
264-272Informations de copyright
Copyright © 2020 The Author(s).